Latest Industry Insights

Technology Networks spoke to Emily Jackson-Holmes to learn more about the benefits of AAV vectors and reasons for the growing interest in their use.

In this interview, Joyce explains the impact her work could have on society, tells us about the benefits that open-source technology has had on her research and highlights the importance of researcher support programs.

Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.

Quick to Clinic from Thermo Fisher Scientific aims to accelerate preclinical development, enabling more rapid biologic drug development. To learn more about this solution, we spoke to Paul Jorjorian.

Brain-computer interface (BCI) developer Blackrock Neurotech has announced that its MoveAgain BCI has received Breakthrough Device designation from the US Food and Drug Administration (FDA). To find out more, we spoke with Blackrock’s chairman and president, Florian Solzbacher.

We spoke to co-founder and executive chairman, Ronan Levy, to find out more about Field Trip’s approach to psychedelic therapy and why 2021 has been such a significant year in psychedelics.

In this interview, Patrick Brown tells us more about the evolution of NanoDrop over the past 20 years, highlights some of the most important improvements during this time and explores what the future may hold for the technology.

In this interview, Greg Gosch shares insights into the science of multiplexing, discusses how ChromaCode is redefining molecular diagnostics and explores how HDPCR is shaping the future of what’s possible in COVID-19, related respiratory and other disease testing.

In this instalment of Science Futures, we hear from Tijmen Bos, a PhD candidate at the Vrije Universiteit Amsterdam and the University of Amsterdam. Tijmen discusses the impact his research could have on society and how interactions with industry have helped progress his research and prepare him for the end of his PhD.

Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.